Saxon Ridley's research while affiliated with Norfolk and Norwich University Hospitals NHS Foundation Trust and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Critical illness is an emergency because the inflammatory response has redundant multiple pathways; once triggered, it is difficult to control or suppress. Infection is a potent precursor of critical illness and increasing organ dysfunction has a synergistic, rather than purely additive, adverse effect on mortality. The longer the inflammatory proc...
Thousands of patients suffering from severe sepsis are set to benefit from the publication of the National Institute for Clinical Excellence (NICE) guidelines recommending the use of Xigris (drotrecogin alfa (activated), Eli Lilly & Company Ltd, Basingstoke). Drotrecogin alfa (activated) is the only drug specifically designed to treat severe sepsis...
Citations
... With BSI Admitted to the ICU Most BSI events (72%) were acquired in the ICU. In this cohort, the mortality rate of critically ill patients admitted to the ICU was 78.6% (48 out of 61). Factors significantly associated with mortality were the presence of a Foley catheter at the onset of BSI and the hemodynamic status at the onset of BSI (Table 2). ...
... 8 This suggested an adverse risk-benefit ratio when DrotAA was given to patients at a low risk of death, particularly following surgery, and the EMEA licence was altered accordingly. These concerns have been rebuffed by various authors, 9,10 and a number of nonrandomised case-matched studies have suggested a similar treatment effect to that seen in PROWESS. 2,3,11 However, together with a large proportion of the intensive care community, we were cautious about introducing DrotAA into our clinical practice, awaiting a determination from the UK National Institute for Clinical Excellence, which produced supportive guidance in 2004. ...
